Haemonetics (HAE) announces CSL has informed it of its intent not to renew its Supply Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/20/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Haemonetics (HAE) PT Lowered to $108 at Needham & Company; 'CSL Loss a Gut Punch But Not a Knock-Out'
April 19, 2021 12:06 PM EDTNeedham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $108.00 (from $158.00) while maintaining a Buy rating after the company announced that CSL Plasma will not renew its supply agreement for the use of the PCS2 Plasma Collection System which expires on... More
